Nurix Therapeutics Receives FDA Fast-Track Designation for NX-5948
Nurix Therapeutics has received fast-track designation from the FDA for its treatment, NX-5948, for certain types of lymphocytic cancer....
chronic lymphocytic leukemia
Eli Lilly’s Jaypirca Receives FDA Approval for Leukemia Treatment
In a major breakthrough, the FDA has granted approval to Eli Lilly's Jaypirca for the treatment of adults with...
Eli Lilly’s Jaypirca Receives FDA Approval for Leukemia Treatment
In a major breakthrough, the FDA has granted approval to Eli Lilly's Jaypirca for the treatment of adults with...
Curis Inc. Stock Rises as Analysts See Potential Take-Out Target
Shares of Curis Inc., a cancer-focused biotech company, rose nearly 6% after Truist Securities analysts initiated coverage with a...
Bristol Myers Receives FDA Priority Review for Expanded Breyanzi Label
Bristol Myers Squibb has received priority review from the FDA for its CAR-T cell therapy Breyanzi, which is seeking...